Serum biomarker release patterns following alcohol septal ablation for treatment of hypertrophic cardiomyopathy

References

• Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–255.
   PubMed Web of Science ®Google Scholar
• Kimmelstiel C. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004;109(4):452–456.
   Web of Science ®Google Scholar
• Knight C. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95(8):2075–2081.
   Web of Science ®Google Scholar
• Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;(346):211–214.
   Google Scholar
• Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49(3):350–357.
   Web of Science ®Google Scholar
• Hage FG, Aqel R, Aljaroudi W, et al. Correlation between serum cardiac markers and myocardial infarct size quantified by myocardial perfusion imaging in patients with hypertrophic cardiomyopathy after alcohol septal ablation. Am J Cardiol. 2010;105(2):261–266.
   Web of Science ®Google Scholar
• Adams J. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. 1993;88(1):101–106.
   PubMed Web of Science ®Google Scholar
• Wu A. Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. Ann Clin Lab Sci. 1996;26(4):291–300.
   Web of Science ®Google Scholar
• Madsen LH, Lund T, Grieg Z, et al. Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation. Cardiology. 2009;114(3):167–173.
   Web of Science ®Google Scholar
• Liebetrau C, Mollmann H, Nef H, et al. Release kinetics of cardiac biomarkers in patients undergoing transcoronary ablation of septal hypertrophy. Clin Chem. 2012;58(6):1049–1054.
   PubMed Web of Science ®Google Scholar
• Bradham WS, Gunasinghe H, Holder JR, et al. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002;40(12):2165–2173.
   Web of Science ®Google Scholar
• Sakamoto T, Mizuno Y, Ogawa H, Yoshimura M, Kugiyama K, Yasue H. B-type natriuretic peptide after percutaneous transluminal septal myocardial ablation. Int J Cardiol. 2002;83(2):151–158.
   Web of Science ®Google Scholar
• Liebetrau C, Nef HM, Dorr O, et al. Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction. Heart. 2014;100(8):652–657.
   Web of Science ®Google Scholar
• Lewis GD, Wei R, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest. 2008;118(10):3503–3512.
   PubMed Web of Science ®Google Scholar
• Foley JD 3rd, Sneed JD, Steinhubl SR, et al. Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(5):616–623.
   Web of Science ®Google Scholar
• Foley JD 3rd, Sneed JD, Steinhubl SR, et al. Oral fluids that detect cardiovascular disease biomarkers. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(2):207–214.
   PubMed Web of Science ®Google Scholar
• Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep. 2007;59(6):715–720.
   Web of Science ®Google Scholar
• Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart. 2008;94(6):e21.
   Web of Science ®Google Scholar
• Liebetrau C, Gaede L, Dorr O, et al. Release kinetics of N-terminal pro-B-type natriuretic peptide in a clinical model of acute myocardial infarction. Clin Chim Acta. 2014;429:34–37.
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med. 2011;43(5):331–340.
   PubMed Web of Science ®Google Scholar
• Mather AN, Fairbairn TA, Artis NJ, Greenwood JP, Plein S. Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance. Int J Cardiol. 2013;166(2):458–464.
   Web of Science ®Google Scholar